Pfizer, Inc. · NYSE:PFE
Pfizer — Deutsche Bank Healthcare Conference 2008
20 slides from Pfizer's conference presentation, May 5, 2008
Slide 1: Deutsche Bank Healthcare Conference
Deutsche Bank Healthcare Conference Jeff Kindler Chairman and Chief Executive Officer May 5, 2008
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Discussions at this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward- looking statements. The factors that could cause actual results to differ are discussed in
Slide 3: Jeff Kindler, Chairman and Chief Executive Officer
Jeff Kindler Chairman and Chief Executive Officer
Slide 4: Our Path Forward
Our Path Forward Maximize Revenues from Existing, New & Diverse Sources Take Advantage of Size, Scale of Pfizer Establish a Lower, More Flexible Cost Base Operate with Agility, Speed, Focus of an Entrepreneurial Organization Innovate the Business Model Drive Greater Total Shareholder Return
Slide 5: Our Path Forward: Strategies for Growth
Our Path Forward: Strategies for Growth US Lipitor Post Today LOE Lipitor Optimize the Patent-Protected Portfolio Maximize the Value of New and Inline Products Advance Compounds in the Pipeline Maximize Revenues Capitalize on Established Products Sustainable TSR Growth Grow in Emerging Markets
Slide 6: Optimize the Patent-Protected Portfolio: Maximize New and In-Line Products
Optimize the Patent-Protected Portfolio: Maximize New and In-Line Products +86% +86% +71% +71% Launched 61 countries Launched 56 countries; 20+ in next 12 >90% coverage of U.S. third party months payers Used by 5+ million smokers globally Phase 1, 2 and 3 trials in kidney, liver, Refill
Slide 7: Optimize the Patent-Protected Portfolio: Advance Compounds in the Pipeline
Optimize the Patent-Protected Portfolio: Advance Compounds in the Pipeline Pipeline as of Feb 28, 2008 Approved Selzentry Over 300 Phase 1 Phase 2 Phase 3 In Reg. Discovery Lyrica for 47 37 16 2 Fibromyalgia Projects fesoterodine (EU) (Pipeline as of July 31, 2007) (38) (47) (11) (3) Goals 15–20 P
Slide 8: Optimize the Patent-Protected Portfolio: Disease Area Priorities
Optimize the Patent-Protected Portfolio: Disease Area Priorities Invest to Win First or High Market High Best in Class Growth Unmet Need 9 9 9 Oncology Pain Immunology / Inflammation Diabetes / Obesity Alzheimer’s Disease Schizophrenia Maximize Revenues
Slide 9: Optimize the Patent-Protected Portfolio: Oncology
Optimize the Patent-Protected Portfolio: Oncology The Current Opportunity Opportunity by 2012: = $57.3 B $81 B 7% CAGR Pfizer $2.6 B Pfizer Assets and Advantages: 4% PreClin Phase I Phase II Phase III Market 5 13 6 5 5 Pfizer Strategy: Establish Worldwide Oncology Business Unit 96% Acc
Slide 10: Capitalize on Established Products
Capitalize on Established Products Opportunity by 2012: The Current Opportunity = $271 B $523 B 11% CAGR Pfizer Pfizer Assets and Advantages: $12 B Excellent portfolio of products 4% Strong brand recognition for innovation, quality and safety Cutting-edge manufacturing technology Bro
Slide 11: The Market Is Not Homogenous, Three Distinct Market Segments
The Market Is Not Homogenous, Three Distinct Market Segments Dispensing Drivers: Payers and Pharmacy Channel, with Physician Branded Emerging Markets and Pharmacy Influence Branded Traditional Markets IP-Driven Markets Brand: Moderately Important 2012 Size: $130B LOE Cliff: Moderate Dispensing
Slide 12: Grow in Emerging Markets
Grow in Emerging Markets Opportunity by 2011: The Current Opportunity $225 B = $149 B 11% CAGR Pfizer Pfizer Assets and Advantages: $5 B Ability to leverage global scale, 3% product breadth and growing oncology portfolio Increasing R&D focus, including R&D incubator, Asian investment fun
Slide 13: Why We Believe We Will Succeed in Established Products and Emerging Markets
Why We Believe We Will Succeed in Established Products and Emerging Markets Pfizer has Unique Competitive Advantages Large Diversified Portfolio Tremendous Brand Recognition for Quality Strong Presence in the Right Geographies Experienced Local Talent Close to the Operations Maximize Revenue
Slide 14: Proven Track Record of Managing Costs
Proven Track Record of Managing Costs 12/31/04(1) 3/30/08 Change Manufacturing Sites 78 57 (27%) Outsourced Manufacturing (%) 9% 17% 8 pts. R&D Sites 15 10 (33%) Total Real Estate Sq. Footage 80 54 (33%) (in millions) Sales Force 36,300 28,000 (23%) Total Headcount 110,000 85,000 (23%) (1) In the fi
Slide 15: Plans for Continued Cost Management
Plans for Continued Cost Management Manufacturing Research and Development Increasing outsourced manufacturing to Utilizing Enhanced Clinical Trial Design 30%, while maintaining quality Applying Biotech Investment Paradigm Reducing network of manufacturing plants Using Centers of Emphasis
Slide 16: Slide 16
Slide 17: Innovate the Business Model: Pharmaceutical Operations
Innovate the Business Model: Pharmaceutical Operations Change Benefits Realized Reduced the field force by about 20% Launched Lyrica fibromyalgia indication 2 months 5 U.S. Business earlier than would have been done under the prior Units model Formation of highly-trained, razor sharp field for
Slide 18: Innovate the Business Model: Research and Development
Innovate the Business Model: Research and Development Change Benefits Realized Instituted Accelerated 20 high value programs and terminated 23 New programs Compound Review Identified 6 key disease areas to ‘Invest to Win’ Process Initiated Phase 3 starts of the following: Moved to IGF-1R
Slide 19: Our Path Forward
Our Path Forward Maximize Revenues from Existing, New & Diverse Sources Take Advantage of Size, Scale of Pfizer Establish a Lower, More Flexible Cost Base Operate with Agility, Speed, Focus of an Entrepreneurial Organization Innovate the Business Model Drive Greater Total Shareholder Return
Slide 20: Jeff Kindler, Chairman and Chief Executive Officer
Jeff Kindler Chairman and Chief Executive Officer